Zarif Attalla, K.; Hassan, D.H.; Teaima, M.H.; Yousry, C.; El-Nabarawi, M.A.; Said, M.A.; Elhabal, S.F.
Enhanced Intranasal Delivery of Atorvastatin via Superparamagnetic Iron-Oxide-Loaded Nanocarriers: Cytotoxicity and Inflammation Evaluation and In Vivo, In Silico, and Network Pharmacology Study for Targeting Glioblastoma Management. Pharmaceuticals 2025, 18, 421.
https://doi.org/10.3390/ph18030421
AMA Style
Zarif Attalla K, Hassan DH, Teaima MH, Yousry C, El-Nabarawi MA, Said MA, Elhabal SF.
Enhanced Intranasal Delivery of Atorvastatin via Superparamagnetic Iron-Oxide-Loaded Nanocarriers: Cytotoxicity and Inflammation Evaluation and In Vivo, In Silico, and Network Pharmacology Study for Targeting Glioblastoma Management. Pharmaceuticals. 2025; 18(3):421.
https://doi.org/10.3390/ph18030421
Chicago/Turabian Style
Zarif Attalla, Kristina, Doaa H. Hassan, Mahmoud H. Teaima, Carol Yousry, Mohamed A. El-Nabarawi, Mohamed A. Said, and Sammar Fathy Elhabal.
2025. "Enhanced Intranasal Delivery of Atorvastatin via Superparamagnetic Iron-Oxide-Loaded Nanocarriers: Cytotoxicity and Inflammation Evaluation and In Vivo, In Silico, and Network Pharmacology Study for Targeting Glioblastoma Management" Pharmaceuticals 18, no. 3: 421.
https://doi.org/10.3390/ph18030421
APA Style
Zarif Attalla, K., Hassan, D. H., Teaima, M. H., Yousry, C., El-Nabarawi, M. A., Said, M. A., & Elhabal, S. F.
(2025). Enhanced Intranasal Delivery of Atorvastatin via Superparamagnetic Iron-Oxide-Loaded Nanocarriers: Cytotoxicity and Inflammation Evaluation and In Vivo, In Silico, and Network Pharmacology Study for Targeting Glioblastoma Management. Pharmaceuticals, 18(3), 421.
https://doi.org/10.3390/ph18030421
